Author:
Zheng Jiarui, ,Wang Xiaoxiao,Wang Zilong,Huang Linxiang,Xie Yandi,Jiang Suzhen,Feng Bo,
Publisher
Chinese Center for Disease Control and Prevention
Reference21 articles.
1. Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (Version 2022). Chin J Infect Dis 2022;30(12):1309 − 31. http://dx.doi.org/10.3760/cma.j.cn501113-20221204-00607. (In Chinese).
2. Martin P, Nguyen MH, Dieterich DT, Lau DTY, Janssen HLA, Peters MG, et al. Treatment algorithm for managing chronic hepatitis b virus infection in the united states: 2021 update. Clin Gastroenterol Hepatol 2022;20(8):1766 − 75. http://dx.doi.org/10.1016/j.cgh.2021.07.036.
3. Nguyen VTT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009;16(7):453 − 63. http://dx.doi.org/10.1111/j.1365-2893.2009.01117.x.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65 − 73. http://dx.doi.org/10.1001/jama.295.1.65.
5. Meng C, Liu T, Liu YW, Zhang LZ, Wang YL. Hepatitis B virus cccdna in hepatocellular carcinoma tissue increases the risk of recurrence after liver transplantation. Transplant Proc 2019;51(10):3364 − 8. http://dx.doi.org/10.1016/j.transproceed.2019.04.020.